Results 261 to 270 of about 391,709 (316)
Some of the next articles are maybe not open access.

AMPA Receptor Antagonists

Current Medicinal Chemistry, 2001
AMPA Receptor antagonists have received considerable attention in recent years. Within the class of excitatory amino acid receptor antagonists AMPA receptor antagonists have shown excellent neuroprotection in several models of cerebral ischemia and neuronal injury.
Sham Shridhar Nikam   +1 more
openaire   +2 more sources

AT1 Receptor Antagonists

Current Medicinal Chemistry-Cardiovascular & Hematological Agents, 2004
Type 1 receptors (AT1) for the peptide hormone angiotensin II play a crucial role in the cardiovascular homeostasis. In this regard, several selective, orally active non-peptide antagonists have been developed for the treatment of hypertension and congestive heart failure.
Ilse Verheijen   +3 more
openaire   +3 more sources

Prolactin Receptor Antagonists

Endocrine, 1998
Most prolactin (PRL) in the circulation is produced by the pituitary. However, a wide variety of traditional target tissues of the hormone have also been shown to produce their own prolactin. The amount produced per cell is low, but may well be sufficient for autocrine/paracrine activity.
Chiaoyun Benson Kuo   +2 more
openaire   +3 more sources

Bradykinin receptors and their antagonists

European Journal of Pharmacology, 1998
Bradykinin and related kinins act on two receptor types, named B1 and B2. Initially identified in classical bioassays, these receptors have been cloned and characterized in binding assays performed on plasma membranes of cells expressing the native or the transfected human kinin B1 or B2 receptor types.
Fernand Junior Gobeil   +3 more
openaire   +2 more sources

Neurokinin receptor antagonists

Expert Opinion on Investigational Drugs, 2000
Studies on tachykinin peptides and the corresponding neurokinin receptors (NKr) have increased dramatically recently due to the discovery of selective, orally-active, metabolically stable and sometimes CNS penetrating NKr antagonists. After demonstrating the potential use for NKr antagonists in animal models, some compounds have recently progressed ...
Vincent Leroy   +3 more
openaire   +3 more sources

Vasopressin Receptor Antagonists

Current Hypertension Reports, 2015
Arginine vasopressin (AVP) is the principal hormone involved in regulating the tonicity of body fluids. Less appreciated is the role that AVP plays in a variety of other physiologic functions including glucose metabolism, cardiovascular homeostasis, bone metabolism, and cognitive behavior.
openaire   +2 more sources

Cholecystokinin receptor antagonists

American Journal of Physiology-Gastrointestinal and Liver Physiology, 1984
Since 1979 three classes of cholecystokinin receptor antagonists have been described: 1) derivatives of cyclic nucleotides, 2) derivatives of amino acids, and 3) C-terminal fragments or partial sequences of cholecystokinin. These various antagonists share a number of common features, such as their specific, reversible, and competitive actions, but ...
R. T. Jensen, J. D. Gardner
openaire   +3 more sources

Endothelin receptor antagonists

Pharmacology & Therapeutics, 2006
Endothelin receptor antagonists (ERAs) have been developed to block the effects of endothelin-1 (ET-1) in a variety of cardiovascular conditions. ET-1 is a powerful vasoconstrictor with mitogenic or co-mitogenic properties, which acts through the stimulation of 2 subtypes of receptors [endothelin receptor subtype A (ETA) and endothelin receptor subtype
Motte, Sophie   +2 more
openaire   +5 more sources

Mineralocorticoid receptor antagonists

Current Hypertension Reports, 2007
With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of
Parthasarathy, Hari Krishnan   +1 more
openaire   +4 more sources

Bradykinin receptor antagonists

Medicinal Research Reviews, 1990
Bradykinin and its active metabolites are produced at the sites of their actions by kallikreins. They potently elicit a variety of biological effects: hypotension, bronchoconstriction, gut and uterine contraction, epithelial secretion in airway, gut, and exocrine glands, vascular permeability, pain, connective tissue proliferation, and eicosanoid ...
Stephen G. Farmer   +2 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy